m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01665)
Name
Ro-43-5054
Synonyms
Ro-43-5054; CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)
    Click to Show/Hide
Status
Terminated
Structure
Formula
C20H27N5O7
InChI
1S/C20H27N5O7/c1-10(2)16(20(31)32)25-19(30)13(9-15(27)28)24-14(26)7-8-23-18(29)12-5-3-11(4-6-12)17(21)22/h3-6,10,13,16H,7-9H2,1-2H3,(H3,21,22)(H,23,29)(H,24,26)(H,25,30)(H,27,28)(H,31,32)/t13-,16-/m0/s1
InChIKey
RRUJJOMANFUDEN-BBRMVZONSA-N
PubChem CID
44343754
TTD Drug ID
D0Z0XQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
ITGB3 messenger RNA (ITGB3 mRNA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Ro-43-5054. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-43-5054 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). [1], [2]
References
Ref 1 Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res. 2019 Sep 15;79(18):4612-4626. doi: 10.1158/0008-5472.CAN-19-0799. Epub 2019 Jul 22.
Ref 2 Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. doi: 10.1021/jm000022w.